Crohn's disease is a chronic inflammatory bowel disease (IBD) characterized by transmural inflammation that can affect any part of the gastrointestinal tract, most commonly the terminal ileum and colon. Clinical trials in Crohn's have been among the most innovative in gastroenterology — the development of vedolizumab, ustekinumab, risankizumab, and upadacitinib have each added meaningful options for patients failing anti-TNF therapy, and the field continues to advance toward mucosal healing and histological remission as endpoints.
Active trials investigate mirikizumab (IL-23 inhibitor), guselkumab, jaktinib and other selective JAK inhibitors, ozanimod (S1P modulator approved for UC, under study for CD), autologous stem cell transplantation for refractory disease, and fecal microbiome transplant (FMT) protocols. Biomarker-driven trials using fecal calprotectin, CRP, and endoscopy-based transmural healing scores are becoming primary registration endpoints.
Crohn's disease trials typically require endoscopic confirmation of active mucosal disease (CD Endoscopic Index of Severity ≥7 or SES-CD ≥6); prior biologic failure is required for most second- and third-line trials.
Frequently Asked Questions — crohns disease Clinical Trials
How many clinical trials are currently recruiting for crohns disease?
ClinicalMetric currently tracks 2 actively recruiting clinical trials for crohns disease, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 2. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for crohns disease?
crohns disease research spans multiple clinical trial phases. Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a crohns disease clinical trial?
Eligibility criteria for crohns disease trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Top Sponsors
Icahn School of Medicine at Mount Sinai 1 trial
Alimentiv Inc. 1 trial
Recruiting Clinical Trials
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional.
Full Disclaimer ·
Last Reviewed: April 2026 ·
Data Methodology